Patent Grant
8535928
This application is a U.S. national stage of International Application No. PCT/JP2009/063547 filed Jul. 30, 2009.
The present invention relates to a novel protease and use thereof. In particular, the present invention relates to a novel protease having a high activity under high temperature and high alkaline conditions, and a pro-form thereof, a polynucleotide encoding the protease or the pro-form, and use of the protease, the pro-form or the polynucleotide.
Protease is a collective term for enzymes catalyzing hydrolysis of peptide bonds and is present ubiquitously in microorganisms, animals and plants. A protease is also a typical industrial enzyme and is used extensively in the fields of detergents, leather processing, food processing and functional peptide production. Particularly, from the viewpoint of prevention of secondary infection via medical apparatus, there are few alternative solutions to protease-mediated degradation of infectious protein contaminants on medical apparatus. For practical use, the most important properties of an industrial enzyme are high stability and high activity under the conditions of use. Particularly, high physicochemical stability to heat is often required and thus heat-resistant proteases are extensively used as an industrial protease. Currently, as an industrial protease, subtilisin family proteases such as subtilisin carlsberg and Proteinase K are known. In particular, Prionzyme available from the U.S. company Genencor has the highest stability among commercial proteases and is used for apparatus cleansing which is intended to prevent transmission of abnormal prion proteins, which are causative agents of prion diseases such as CJD (Creutzfeldt-Jakob disease). However, the optimum conditions for Prionzyme are limited to a temperature of 40 to 60° C. and a pH of 8 to 10, and there has been a desire for practical application of proteases usable at higher temperature conditions. Accordingly, many attempts have been made to find a novel protease usable under high temperature and high alkaline conditions.
For example, the present inventors found a subtilisin family protease derived from a hyperthermophilic archaeon, Thermococcus kodakaraensis KOD1 (hereinafter referred to as “Tk-subtilisin”), and reported that Tk-subtilisin shows the highest activity at pH 9.5 at a temperature of 80 to 100° C. among various conditions and has the highest thermostability among known proteases (see nonpatent literature 1 and 2). The patent literature 1 discloses a heat-resistant protease derived from the same Thermococcus kodakaraensis KOD1 and reports that the optimum temperature for this heat-resistant protease is about 80° C., that the protease has such a heat resistance that the residual activities are about 75% and about 50% after 120 minute-incubation at 70° C. and 80° C., respectively, and that the protease has such an alkali resistance that the residual activities are 90% or more and about 85% after 120 minute-incubation at pH 11 and pH 11.5, respectively.
Non Patent Literature 1:
As exemplified by the protease described in the nonpatent literature 1 and 2, and the heat-resistant protease described in the patent literature 1, novel proteases usable under high temperature and high alkaline conditions have been already found, but not yet used practically. Industrial proteases are often used as an ingredient of detergents and thus need to be stable and active even in the presence of surfactants. Therefore, a major challenge in the technical field concerned is still to find a further novel protease, to clarify its function and then to put the protease into practical use as an industrial protease through research and development.
Accordingly, an object of the present invention is to provide a novel protease which has a high activity under high temperature and high alkaline conditions, a high stability to protein denaturants and surfactants and high effectiveness as a protease used in detergents.
In order to achieve the object, the present invention includes the following inventions.
The present invention can provide a protease which, in comparison with conventional ones, has a higher activity under high temperature and high alkaline conditions, a higher stability to protein denaturants and surfactants, and the capability of degrading a low concentration of substrates. This protease is greatly useful as a protease that can be blended into any of various detergents for use under high temperature and high alkaline conditions.
a) is an image showing the SDS-PAGE results of the pro-form of the present invention (proTk-SP).
(1) Preparation of Protease
The protease of the present invention is a novel protease derived from a hyperthermophilic archaeon, Thermococcus kodakaraensis KOD1 (Morikawa M et al. Appl Environ Microbiol, 1994 December; 60 (12): 4559-66, hereinafter referred to as KOD1). KOD1 was deposited with the independent administrative institution RIKEN BioResource Center under the accession number JCM12380. The complete genome of KOD1 was already decoded, in which 2036 protein coding regions (CDSs) were identified and about half of them (1165 CDSs) were annotated (Fukui T et al., Genome Res, 2005 March; 15 (3): 352-63). The 2088737-bp complete genome sequence of KOD1 was registered with DDBJ/EMBL/GenBank under the accession number AP006878.
Based on the genomic information on KOD1, the present inventors focused their attention to the base sequence predicted to encode a subtilisin-like serine protease precursor (ACCESSION: AP006878 REGION: 1484233 . . . 1486224, SEQ ID NO: 8), and identified a specified partial sequence of the full length protein encoded by the base sequence as the one which constitutes a mature protein having protease activity. Generally, proteases of the subtilisin family have a long pre-pro sequence. It is said that the proteases require a pre-sequence (also called a signal sequence) for their exocytic release and a pro-sequence for formation of their active conformation. Then, based on the base sequence (SEQ ID NO: 8), the present inventors amplified DNA of the region predicted to encode the protease precursor (pro-form), which has the pro-sequence and the mature sequence but excludes the pre-sequence (signal sequence). The present inventors inserted the resulting DNA fragment into an expression vector and transferred the expression vector into Escherichia coli for expression of the objective protein (pro-form). By incubating the resulting pro-form for processing (maturation), for example at pH 9 at 80° C. for 120 minutes, the present inventors obtained a mature protein having protease activity, i.e. the protease of the present invention.
The protease of the present invention comprises any one of the following amino acid sequences (a) to (d).
The amino acid sequence of SEQ ID NO: 1 corresponds to the region from residue 137 to residue 562 of the amino acid sequence (ACCESSION: BAD85878, SEQ ID NO: 7) deduced from the base sequence predicted to encode the above-mentioned subtilisin-like serine protease precursor (ACCESSION: AP006878 REGION: 1484233 . . . 1486224, SEQ ID NO: 8). The amino acid sequence of SEQ ID NO: 3 corresponds to the region from residue 137 to residue 563 of the amino acid sequence (SEQ ID NO: 7) deduced from the base sequence predicted to encode the above-mentioned subtilisin-like serine protease precursor (SEQ ID NO: 8).
The pro-form of the present invention is a pro-form of the protease of the present invention and comprises the following amino acid sequence (e) or (f).
As used herein, the term “pro-form” refers to a protease precursor which has a pro-sequence and a mature sequence but no pre-sequences.
The amino acid sequence of SEQ ID NO: 5 corresponds to the region from residue 24 to residue 663 of the amino acid sequence (SEQ ID NO: 7) deduced from the base sequence predicted to encode the above-mentioned subtilisin-like serine protease precursor (SEQ ID NO: 8). The one which excludes the region of residue 1 to residue 113 and the region of residue 540 to residue 640 from the amino acid sequence of the pro-form (SEQ ID NO: 5) is a protease comprising the amino acid sequence of SEQ ID NO: 1. The one which excludes the region of residue 1 to residue 113 and the region of residue 541 to residue 640 from the amino acid sequence of the pro-form (SEQ ID NO: 5) is a protease comprising the amino acid sequence of SEQ ID NO: 3.
As used herein, “having deletion, substitution or addition of one to several amino acids” means having deletion, substitution or addition of an amino acid(s), the number of which is in the range allowed by a known preparation method for mutant peptides, such as site-directed mutagenesis (preferably 10 or less, more preferably 7 or less, and even more preferably 5 or less). Such a mutant protein is not limited to a protein artificially mutated by a known preparation method for mutant polypeptides, and may be a protein isolated and purified from nature. It is well known in the art that modification to some amino acids in the amino acid sequence of a protein can be easily made without any significant effect on the structure or function of the protein. In addition to such artificial modification, it is also well known that there are natural mutants having no significant changes in the structure or function in comparison with wild-type proteins.
A preferable mutant has a conservative or non-conservative amino acid substitution, deletion or addition. More preferably, the mutant has a silent substitution, deletion or addition, and particularly preferably a conservative substitution, none of which alter the polypeptide activity of the present invention. Typical examples of the conservative substitution include substitution whereby one amino acid is exchanged for another among aliphatic amino acids Ala, Val, Leu and Ile, exchange between hydroxyl residues Ser and Thr, exchange between acidic residues Asp and Glu, substitution between amide residues Asn and Gln, exchange between basic residues Lys and Arg, and substitution between aromatic residues Phe and Tyr.
The protease and the pro-form of the present invention may contain an additional peptide. Examples of the additional peptide include epitope peptides for labelling, such as a polyhistidine tag (His-tag), Myc and FLAG.
The protease and the pro-form of the present invention can be prepared by (I) culturing bacteria which produce the protease of the present invention and then conducting isolation and purification of the protease or the pro-form. The protease and the pro-form can be also prepared by (II) a known genetic engineering technique, specifically, by isolating a gene encoding the protease or pro-form of the present invention from bacteria, constructing a recombinant expression vector and then transferring the vector into an appropriate host cell for expression of a recombinant protein. Alternatively, the protease and the pro-form can be prepared by (III) in vitro coupled transcription-translation system. Bacteria that can be used for preparation of the protease of the present invention are not particularly limited as long as they can produce the protease of the present invention. Preferable examples of the bacteria include KOD1 described above.
In the case where the above method (I) is employed with KOD1, culture of KOD1 can be performed under the culture conditions described in Morikawa. et al. Appl. Environ. Microbiol. 60: 4559-4566. (1994), for example. After several days of the culture, the KOD1 cells are removed from the culture medium and the protease or the pro-form is separated and purified from the remaining culture medium by a known technique, specifically including separation techniques such as salting-out, precipitation and ultrafiltration; purification techniques such as ion exchange chromatography, isoelectric chromatography, hydrophobic chromatography, gel filtration chromatography, adsorption chromatography, affinity chromatography and reversed phase chromatography; and a combination of the foregoing techniques.
The above method (II) will be described in detail in the sections below of [polynucleotide], [expression vector] and [transformant].
In the case where the above method (III) is employed, a DNA fragment encoding the protease or pro-form of the present invention can be used with a known in vitro coupled transcription-translation system (for example, a system using cell-free extract of Escherichia coli, wheat germ cells or rabbit retinal cells).
Identification of the thus obtained protease or pro-form can be performed using a known method. For example, the obtained protease is separated by polyacrylamide gel electrophoresis and then transferred to a polyvinylidene fluoride (PVDF) membrane, and after Coomassie Brilliant Blue staining, the band of the objective protein is excised from the stained membrane. Using tryptic digest of the band, peptide mass fingerprinting can be performed by MALDI-TOF MS for protein identification. Also, amino acid sequence determination can be performed, for example, using an automated peptide sequencer.
(2) Biochemical Properties of Protease
(i) Optimum pH (See Example 2)
In the case where the protease of the present invention is incubated with Suc-AAPF-pNA serving as a substrate at 20° C. for 10 minutes, the optimum pH ranges at least from 6 to 11.5, and it is expected that the high activity is maintained even above pH 11.5. Thus, the protease of the present invention is suitable for use in diverse pH environments at pH 6 or above.
(ii) Optimum Temperature (See Example 3)
In the case where the reaction of the protease using azocasein as a substrate is performed at pH 7 for 20 minutes, the optimum temperature is 100° C. or higher. Thus, the protease of the present invention is suitable for use in high temperature environments, and for example, when blended into detergents for medical apparatus which are intended for degradation of infectious protein contaminants, the protease can be expected to provide an excellent effect.
(iii) Thermostability (See Example 4)
After the protease is treated in a solution at 100° C. for 90 minutes, the residual activity is 40% or more. After the protease is treated in a solution at 90° C. for 180 minutes, the residual activity is 80% or more. After the protease is treated at 80° C. for 180 minutes, the activity of the protease remains unchanged from that before the heat treatment. Thus, the protease of the present invention, which has an extremely high thermostability, is suitable for use in high temperature environments.
(iv) Stability to Protein Denaturants, Surfactants and Chelating Agents (See Example 5)
After the protease is treated in 20 mM Tris-HCl (pH 8) containing 8 M urea at 55° C. for 60 minutes, the residual activity is 80% or more.
After the protease is treated in 20 mM Tris-HCl (pH 8) containing 2 M guanidine hydrochloride at 55° C. for 60 minutes, the residual activity is 60% or more.
After the protease is treated in 20 mM Tris-HCl (pH 8) containing 10% Triton X-100 at 55° C. for 60 minutes, the residual activity is 95% or more.
After the protease is treated in 20 mM Tris-HCl (pH 8) containing 10% Tween 20 at 55° C. for 60 minutes, the residual activity is 95% or more.
After the protease is treated in 20 mM Tris-HCl (pH 8) containing 5% sodium dodecyl sulfate at 55° C. for 60 minutes, the residual activity is 80% or more.
After the protease is treated in 20 mM Tris-HCl (pH 8) containing 10 mM EDTA at 55° C. for 60 minutes, the activity of the protease remains unchanged from that before the treatment.
Thus, the protease of the present invention, which has a high stability to various kinds of protein denaturants, surfactants and chelating agents, is advantageous in that the protease can be blended into a composition containing a protein denaturant, a surfactant and/or a chelating agent and also used as an industrial protease in a wide range of applications.
(v) Km Value (See Example 7)
In the case where the reaction of the protease using Suc-AAPF-pNA as a substrate is performed at 80° C., the Km value is 0.1 to 1 mM. This value is about 1/10 of the Km value of the above-mentioned Tk-subtilisin (see nonpatent literature 1 and 2), suggesting that, in comparison with Tk-subtilisin, the protease of the present invention can more efficiently degrade a low concentration of the substrate. Thus, the protease of the present invention can be preferably used in various applications including detergents for medical apparatus (infectious protein contaminants on medical apparatus may cause secondary infection).
(vi) Calcium Ion Non-Requirement for Structure Formation (See Example 8)
The protease of the present invention does not require calcium ions for structure formation and can exert a stable protease activity even in the absence of calcium ions.
This is one of the characteristics of the protease of the present invention in contrast to Tk-subtilisin, a protease derived from the same Thermococcus kodakaraensis KOD1, which shows an extremely strong calcium requirement. Thus, the protease of the present invention has an extremely excellent advantage that it can exert a stable activity, for example, even in a detergent containing a chelating agent as an additive.
The activity of the protease of the present invention can be determined in accordance with the descriptions in the Examples below. To be more specific, the protease is allowed to hydrolyze peptide bonds in a substrate such as Suc-AAPF-pNA and azocasein and the chromogen released from the substrate is quantified based on the absorbance. In this way, the amount of the peptide bond cleaved by the enzyme can be calculated, and thus the enzyme activity can be determined.
[Polynucleotide]
The polynucleotide of the present invention encodes the protease of the present invention. Specific examples thereof include the following polynucleotides (A) to (D).
In another aspect of the present invention, the polynucleotide encodes the pro-form of the present invention. Specific examples thereof include the following polynucleotides (E) and (F).
As used herein, the term “polynucleotide” is interchangeable with the term “gene”, “nucleic acid” or “nucleic acid molecule”. The polynucleotide of the present invention can be present in the form of RNA (for example, mRNA) or DNA (for example, cDNA or genomic DNA). DNA may be a double strand or a single strand. A single-stranded DNA or RNA may be a coding strand (sense strand) or a non-coding strand (antisense strand). The polynucleotide of the present invention may be fused with a polynucleotide encoding a tag for labelling (a tag sequence or a marker sequence) at the 5′- or 3′-terminus.
Preferably, the polynucleotide encoding the protease of the present invention is a polynucleotide comprising the base sequence of SEQ ID NO: 2 or 4, or a polynucleotide which encodes a protease and hybridizes to a polynucleotide comprising the complementary base sequence of SEQ ID NO: 2 or 4 under stringent conditions.
Preferably, the polynucleotide encoding the pro-form of the present invention is a polynucleotide comprising the base sequence of SEQ ID NO: 6, or a polynucleotide which encodes a pro-form and hybridizes to a polynucleotide comprising the complementary base sequence of SEQ ID NO: 6 under stringent conditions.
The base sequence of SEQ ID NO: 2 corresponds to the region from position 409 to position 1686 of the base sequence predicted to encode the above-mentioned subtilisin-like serine protease precursor (ACCESSION: AP006878 REGION: 1484233 . . . 1486224, SEQ ID NO: 8), and the base sequence of SEQ ID NO: 4 corresponds to the region from position 409 to position 1689 of SEQ ID NO: 8. The base sequence of SEQ ID NO: 6 corresponds to the region from position 70 to position 1992 of SEQ ID NO: 8.
Hybridization can be performed according to a well-known method as described in Sambrook et al., Molecular Cloning, A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory (2001). Usually, as the temperature becomes higher and the salt concentration becomes lower, the conditions of hybridization become more stringent (this means that hybridization becomes harder to achieve), and thereby more homologous polynucleotides can be obtained. A suitable hybridization temperature varies with the base sequence and the length thereof, and for example, in the case where an 18-base DNA fragment encoding 6 amino acids is used as a probe, the temperature is preferably 50° C. or lower.
The procedure for “hybridizes under stringent conditions” means that the filter is incubated in a hybridization solution (50% formamide, 5×SSC (150 mM NaCl and 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate and 20 μg/ml denatured sheared salmon sperm DNA) at 42° C. overnight and then washed in 0.1×SSC at about 65° C.
Preferably, the polynucleotide of the present invention encodes a protease and comprises a base sequence having at least 80% homology, more preferably at least 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% homology to the complementary base sequence of SEQ ID NO: 2 or 4. Preferably, the polynucleotide of the present invention encodes a pro-form and comprises a base sequence having at least 80% homology, more preferably at least 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% homology to the complementary base sequence of SEQ ID NO: 6.
Whether a certain polynucleotide is, for example, at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% homologous to the base sequence of SEQ ID NO: 2 can be confirmed by a known computer program (for example, Bestf it program (Wisconsin Sequence Analysis Package, Version 8 for Unix (registered trademark)), Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711).
The polynucleotide of the present invention encompasses, in addition to a double-stranded DNA, a single-stranded DNA or RNA which is a sense or antisense strand constituting a double-stranded DNA. The polynucleotide of the present invention may contain an untranslated region (UTR) sequence, a vector sequence (including an expression vector sequence), etc.
Examples of the method for obtaining the polynucleotide of the present invention include a method using amplification technique such as PCR. For example, based on the 5′- and 3′-terminal sequences of the base sequence of SEQ ID NO: 2 (or their complementary sequences), respective primers are designed, and using these primers and using genomic DNA, cDNA or the like as a template, PCR or the like is conducted to amplify a DNA region flanked by both primers. In this way, a DNA fragment containing the polynucleotide of the present invention can be obtained in a large amount.
[Expression Vector]
The present invention provides an expression vector used for preparation of the protease of the present invention. The expression vector of the present invention is not particularly limited as long as it contains the above-described polynucleotide encoding the polypeptide of the present invention, and for example, plasmid vectors carrying a recognition sequence for RNA polymerase (pSP64, pBluescript, etc.) are preferred. The preparation method for recombinant expression vectors is not particularly limited, and examples thereof include methods using a plasmid, a phage or a cosmid. The kind of the vector is not particularly limited, and a vector that can be expressed in host cells can be appropriately selected. To be more specific, depending on the kind of the host cell, a promoter sequence to ensure the expression of the polynucleotide of the present invention is appropriately selected, and this promoter sequence and the polynucleotide of the present invention are inserted into any of various plasmids etc. for preparation of the expression vector of the present invention.
After a host transformed with the expression vector of the present invention is cultured, cultivated or bred, the protease or pro-form of the present invention can be collected and purified from the cultures etc. according to conventional methods (for example, filtration, centrifugation, cell disruption, gel filtration chromatography, ion exchange chromatography, etc.).
The expression vector preferably contains at least one selection marker. Examples of such a marker include a dihydrofolate reductase gene and a neomycin resistance gene for eukaryotic cell culture; and a tetracycline resistance gene and an ampicillin resistance gene for culture of E. coli and other bacteria. By use of such a selection marker, it can be confirmed whether the polynucleotide of the present invention has been transferred into host cells and then expressed therein without fail. Also, the polypeptide of the present invention may be expressed as a fusion polypeptide. For example, by use of green fluorescent protein (GFP) derived from Aequorea coerulescens as a marker, the polypeptide of the present invention may be expressed as a GFP fusion polypeptide.
The host cell described above is not particularly limited, and various known cells can be preferably used. Specific examples of the host cell include bacteria such as Escherichia coli, yeasts (budding yeast Saccharomyces cerevisiae and fission yeast Schizosaccharomyces pombe), nematodes (Caenorhabditis elegans), Xenopus laevis oocytes and animal cells (for example, CHO cells, COS cells and Bowes melanoma cells). The method for transferring the expression vector described above into host cells, i.e., the transformation method, is not particularly limited, and known methods such as electroporation, the calcium phosphate method, the liposome method and the DEAE dextran method can be used preferably.
[Transformant]
The present invention provides a transformant having the expression vector of the present invention transferred thereinto. As used herein, the term “transformant” encompasses a cell, a tissue and an organ as well as an individual organism. The organism to be transformed is not particularly limited, and examples thereof include various microorganisms, plants and animals mentioned as examples of the host cell described above.
The transformant of the present invention is characterized by expressing the protease or pro-form of the present invention. It is preferable that the transformant of the present invention stably expresses the protease or pro-form of the present invention, but the transformant may transiently express the same.
[Antibody]
The present invention provides an antibody which specifically binds to the protease of the present invention. The antibody of the present invention is preferably an antibody which binds to the protease of the present invention, but not to the precursor thereof. The antibody of the present invention can be used for detection and separation of the protease of the present invention.
As used herein, the term “antibody” refers to an immunoglobulin (IgA, IgD, IgE, IgG, IgM and their fragments (a Fab fragment, a F(ab′)2 fragment, an Fc fragment, etc.)), and examples of the antibody include, but are not limited to, a polyclonal antibody, a monoclonal antibody and a single-chain antibody. The antibody can be prepared according to any of various known methods (for example, Harlow at al., “Antibodies: a laboratory manual”, Cold Spring Harbor Laboratory, New York (1988); and Iwasaki at al., “Monoclonal antibody, hybridoma and ELISA”, Kodansha Ltd. (1991)).
[Application of Protease]
The protease of the present invention, which has a higher activity under high temperature and high alkaline conditions as well as a higher stability to protein denaturants and surfactants in comparison with known industrial proteases, can be blended into detergents for use at a high temperature in order to strengthen their detergency. Further, since the protease of the present invention can degrade a low concentration of substrates, it has high effectiveness for degradation and cleansing of infectious protein contaminants on medical apparatus, which may cause secondary infection. That is, the protease of the present invention can be preferably used for various detergents, such as detergents for medical apparatus, dishwasher detergents and laundry detergents. Also, the protease of the present invention can be used for, in addition to such detergents, feed processing, food processing (fish oil processing, meat processing, etc.), textile processing, wool processing, leather processing, contact lens cleansing, pipe cleaning, etc., and also may be blended into bath salts and depilatories. Further, the protease of the present invention can be used as a protease for sample pretreatment in the preparation of nucleic acids, such as DNA, from tissues and cells.
The present invention provides a detergent (a composition for cleansing) containing the protease of the present invention. The protease content in the detergent is not particularly limited, but because of high activity and high stability to surfactants, even a small amount of the protease can provide a detergent with high detergency. A preferable protease content is, for example, 0.1 to 10% by weight. Too low a protease content cannot provide a sufficient cleansing effect, and conversely, too high a protease content cannot provide an improved cleansing effect proportional to the content, leading to economical inefficiency. The protease of the present invention can be blended into any known detergent without any alteration of the composition of the detergent. There is no particular limitation on the ingredient of the detergent containing the protease of the present invention. A typical example of such a detergent is a detergent containing 10 to 50% by weight of a surfactant, 0 to 50% by weight of a builder, 1 to 50% by weight of an alkaline agent or an inorganic electrolyte, 0.1 to 5% by weight of one or more kinds of ingredients selected from the group consisting of an anti-redeposition agent, an enzyme, a bleaching agent, a fluorescent dye, an anti-caking agent and an antioxidant, relative to the weight of the detergent.
Hereinafter, the present invention will be illustrated in more detail by Examples, but is not limited thereto. In the following Examples, the protease of the present invention is called “Tk-SP” and the pro-form thereof is called “proTk-SP” in some cases.
1-1. Expression and Purification of Pro-Form (proTk-SP)
Based on the genomic information on Thermococcus Kodakaraensis KOD1 (ACCESSION: AP006878), for expression of a pro-form which excludes the putative signal sequence (pre-sequence) from the deduced amino acid sequence (ACCESSION: BAD85878, SEQ ID NO: 7) of the base sequence predicted to encode a subtilisin-like serine protease precursor (ACCESSION: AP006878 REGION: 1484233 . . . 1486224, SEQ ID NO: 8), and contains the putative pro-sequence and mature sequence, a primer pair for amplification of a DNA fragment predicted to encode the pro-form was designed. The primer pair consists of a forward primer having an NdeI site (5′-GGCCTTTATCATATGGCCCCCCAGAAG-3′ (SEQ ID NO: 9)) and a reverse primer having a BamHI site (5′-GGCCTTGGATCCTCACCCGTAGTAAAC-3′ (SEQ ID NO: 10)). Using the primer pair and using the genomic DNA of KOD1 as a template, PCR was performed to amplify the DNA fragment. Digestion of the resulting DNA fragment by NdeI and BamHI gave a 1.9-kb DNA fragment, this fragment was ligated into the NdeI/BamHI site of pET25b (manufactured by Novagen), and thus pET25b-proTk-SP was constructed. With this plasmid (pET25b-proTk-SP), Escherichia coli BL21 (DE3) CodonPlus was transformed into a strain which massively expresses the proTk-SP.
The strain was cultured at 37° C. in a LB culture medium supplemented with 50 μg/ml ampicillin and 34 μg/ml chloramphenicol. When the OD600 value reached 0.8, IPTG was added to the final concentration of 1 mM, and the culture was continued for additional 4 hours. The strain was harvested, suspended in 20 mM Tris-HCl (pH 9.0), sonicated and then centrifuged (30,000×g, 30 min). To the supernatant, 30% ammonium sulfate was added and the resulting precipitate was collected by centrifugation (30,000×g, 30 min). This precipitate was dissolved in 20 mM Tris-HCl (pH 7.0) and the solution was dialyzed against 20 mM Tris-HCl (pH 7.0) for removal of ammonium sulfate. Using the supernatant obtained after the dialysis, purification was performed with the anion exchange column Hitrap Q (manufactured by GE Healthcare).
1-2. Preparation, Molecular Weight Analysis and N-Terminal Analysis of Mature Protein (Tk-SP)
(i) Confirmation of Processing by SDS-PAGE
The purified proTk-SP was dissolved in 1 ml of 50 mM Tris-HCl (pH 9.0) so that the protein concentration was 0.013 mg/ml, and the protein solution was incubated at 80° C. for 120 minutes. After precipitation with TCA, the resulting precipitate was subjected to 15% SDS-PAGE. The results are shown in
(ii) Molecular Weight Analysis by MALDI-TOF MS
The purified proTk-SP was dissolved in 50 mM Tris-HCl (pH 9.0) so that the protein concentration was 1 mg/ml, and the protein solution was incubated at 80° C. for 120 minutes. After the incubation, 1 μl of the protein solution was mixed with 1 μl of a matrix solution (10 mg sinapinic acid in 1 ml of 0.1% TFA and acetonitrile in a volume ratio 2:1), and 1 μl of the mixture was used as a sample for MALDI-TOF MS (manufactured by Bruker Daltonics). The protein standard II was used as a calibration standard. The chart of MALDI-TOF MS is shown in
(iii) N-Terminal Analysis
The processed protein (10 μg) was subjected to 15% SDS-PAGE, and after this, the protein on the gel was transferred to a PVDF membrane by blotting. From the PVDF membrane, a portion to which the objective band was transferred was excised and then subjected to N-terminal analysis by a protein sequencer (Procise automated sequencer, ABI model 491). The results are shown in
From the results of the N-terminal analysis and the molecular weight analysis, the processed protein was considered as a protein comprising the amino acid sequence of residue 114 to residue 539 of SEQ ID NO: 5 (SEQ ID NO: 1, theoretical molecular weight: 44207 Da), or a protein comprising the amino acid sequence of residue 114 to residue 540 of SEQ ID NO: 5 (SEQ ID NO: 3, theoretical molecular weight: 44322 Da). The obtained protein (Tk-SP) with a molecular weight of about 44 kDa was used for the following experiments.
For examination of the pH dependence and the buffer dependence of the Tk-SP, enzyme reactions were performed using acetate buffers (pH 4.5, 5.0, 5.2, 5.4 and 5.6), MES buffers (pH 5.5, 6.0, 6.5 and 7.0), HEPES buffers (pH 7.0 and 7.5), Tris-HCl buffers (pH 7.0, 7.5, 8.0, 8.5 and 9.0), glycine-NaOH buffers (pH 8.5, 9.0, 9.5 and 10.0) and CAPS-NaOH buffers (pH 9.0, 9.5, 10.0, 10.5, 11.0 and 11.5) in the following procedure. 100 μl of a reaction mixture containing a 50 mM buffer and 2 mM Suc-AAPF-pNA (synthetic substrate) was incubated at 20° C. for 5 minutes. To this, 0.1 μg of the Tk-SP was added and the reaction mixture was further incubated at 20° C. for 10 minutes. The reaction was stopped by addition of 10 μl of acetic acid, and then the amount of p-nitroaniline produced from the synthetic substrate Suc-AAPF-pNA was determined by use of the absorption coefficient of 8900 M−1 cm−1 from the absorbance at 410 nm in an ultraviolet spectrophotometer (Beckman model DU640). The amount of the enzyme which catalyzes the production of 1 μmol of p-nitroaniline per minute was defined as “one unit.” The enzyme activity per milligram of the protein was defined as specific activity.
The results are shown in
For examination of the temperature dependence of the Tk-SP, enzyme reactions were performed using azocasein as a substrate at various temperatures ranging from 20 to 100° C. in the following procedure. 270 μl each of a reaction mixture containing 50 mM Tris-HCl (pH 7.0) and 2% azocasein was incubated at a different temperature for 5 minutes. To each reaction mixture, 30 μl of a 3.3 μg/ml solution of the Tk-SP (about 0.1 μg) was added and the reaction mixture was further incubated for 20 minutes. The reaction was stopped by addition of 200 μl of 15% trichloroacetic acid (the final concentration of 6%). After centrifugation (15,000×g, 15 min), 160 μl of the resulting supernatant was mixed with 40 μl of 2 M NaOH and the absorbance at 440 nm (A440) was measured. The amount of the enzyme required to increase the A440 value of 300 μl of the reaction mixture by 1 per minute was defined as “one unit.”
The results are shown in
For examination of the stability of the Tk-SP against irreversible heat inactivation, a Tk-SP solution (3.3 μg/ml Tk-SP, 50 mM Tris-HCl (pH 7)) was treated at 80, 90 and 100° C. After the heat treatment, 30 μl of the Tk-SP solution and azocasein serving as a substrate were used for measurement of the residual activity at 80° C. The measurement procedure was the same as that of Example 3. The residual activity was calculated by division of the activity value after the heat treatment by the activity value before the heat treatment.
The results are shown in
Urea and guanidine hydrochloride (GdnHCl) were used as a protein denaturant. Triton X-100, Tween 20 and sodium dodecyl sulfate (SDS) were used as a surfactant. EDTA was used as a chelating agent. A 0.05 mg/ml solution of the Tk-SP in 20 mM Tris-HCl (pH 8.0) was incubated with the protein denaturant, surfactant or chelating agent described above at 55° C. The concentrations of the protein denaturant and the surfactant were set at 3 to 4 levels. The concentration of EDTA was set at only one level (10 mM). The incubation time was set at 0, 2, 5, 10, 15, 30 and 60 minutes. The activity of the Tk-SP after the incubation was measured at 20° C. by use of Suc-AAPF-pNA as a substrate. The measurement procedure was the same as that of Example 2 except that the pH was 8.
The results on urea are shown in
The results on guanidine hydrochloride (GdnHCl) are shown in
The results on Triton X-100 are shown in
The results on Tween 20 are shown in
The results on sodium dodecyl sulfate (SDS) are shown in
The results on EDTA are shown in
The above results show that the Tk-SP has a high stability to various kinds of protein denaturants, surfactants and chelating agents, and thus has high effectiveness as an industrial protease.
The Tk-SP was incubated with 10 mM EDTA at 80° C. for 30 minutes, and the mixture was dialyzed against 50 mM Tris-HCl (pH 8.0) supplemented with 0.1 mM EDTA. After this, the Tk-SP solution was treated at 80, 90 and 100° C., and the stability of the Tk-SP was examined. The residual activity was measured by use of azocasein as a substrate at 80° C. The measurement procedure was the same as that of Example 3.
The results are shown in
By use of, as a substrate, Suc-AAPF-pNA at various concentrations ranging from 0.01 to 2 mM, the specific activity of the Tk-SP was measured at 20 and 80° C. The measurement procedure was the same as that of Example 2. The obtained values were applied to the Michaelis-Menten equation for calculation of the rate parameters. For comparison, the specific activity of a known thermostable protease, Tk-subtilisin (see nonpatent literature 1) was similarly measured and then the rate parameters thereof were calculated.
The results are shown in Table 1. As shown in Table 1, at either temperature, the Km value of the Tk-SP was smaller than that of Tk-subtilisin (abbreviated to Tk-sub in the table). Therefore, it became clear that the Tk-SP can more efficiently degrade a low concentration of the substrate in comparison with Tk-subtilisin.
A mutant which had protease activity lost by substitution of alanine for serine at residue 359 of the amino acid sequence of the proTk-SP (SEQ ID NO: 5) (hereinafter referred to as “proS359A”) was used. For preparation of the proS359A, a proS359A expression vector was prepared by a known mutagenesis method from pET25b-proTk-SP constructed in Example 1, and transfer of this vector into Escherichia coli and expression and purification of the proS359A were conducted in the same manner as in Example 1.
Whether the proS359A formed the secondary structure was confirmed by circular dichroism measurement (CD spectrum measurement). In the measurement, the protein concentration was 0.1 mg/ml, the buffer used was 20 mM Tris-HCl (pH 7.5), and the temperature was 25° C.
It was confirmed whether the following four samples formed the secondary structure.
The results are shown in
The above results show that the Tk-SP does not require calcium ions for activation, can exert a stable activity even in detergents containing a chelating agent as an additive, and thus is extremely useful.
The present invention is not limited to the aforementioned embodiments and examples, and various modifications can be made within the scope of the appended claims. Other embodiments provided by suitable combination of technical means disclosed in the different embodiments of the present invention are also within the technical scope of the present invention. All the academic publications and patent literature cited in the above description are incorporated herein by reference.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2008-197467 | Jul 2008 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2009/063547 | 7/30/2009 | WO | 00 | 2/10/2011 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2010/013767 | 2/4/2010 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5643777 | Antranikian et al. | Jul 1997 | A |
| 6261822 | Takakura et al. | Jul 2001 | B1 |
| 6358726 | Takakura et al. | Mar 2002 | B1 |
| 6783970 | Takakura et al. | Aug 2004 | B2 |
| 6849441 | Takakura et al. | Feb 2005 | B2 |
| 7144719 | Takakura et al. | Dec 2006 | B2 |
| 7314744 | Takakura et al. | Jan 2008 | B2 |
| 20020086402 | Takakura et al. | Jul 2002 | A1 |
| 20020132335 | Takakura et al. | Sep 2002 | A1 |
| 20050014221 | Takakura et al. | Jan 2005 | A1 |
| 20050084934 | Takakura et al. | Apr 2005 | A1 |
| 20060248617 | Imanaka et al. | Nov 2006 | A1 |
| 20090029416 | Takakura et al. | Jan 2009 | A1 |
| Number | Date | Country |
|---|---|---|
| 2007-006846 | Jan 2007 | JP |
| 9721823 | Jun 1997 | WO |
| 9856926 | Dec 1998 | WO |
| Entry |
|---|
| Q5JIZ5. UnitProtKB Database. Jul. 22, 2008. |
| BAD85878. EMBL Database. May 19, 2007. |
| Current Protocols in Protein Science. John Wiley & Sons, Inc. 5.1-5.1.8. 1995. |
| Sambrook et al. Molecular Cloning, 1989, Cold Spring Harbor Laboratory Press, pp. 8.46-8.52 and pp. 11.2-11.19. |
| Branden et al. Introduction to Protein Structure, Garland Publishing Inc., New York, p. 247, 1991. |
| International Preliminary Report on Patentability (English Translation) issued Apr. 21, 2011 in corresponding International (PCT) Application No. PCT/JP2009/063547. |
| Extended European Search Report issued Apr. 16, 2012 in corresponding European Application No. 09803009.1. |
| Fukui, Toshiaki, et al., “Complete genome sequence of the hyperthermophilic archaeon Thermococcus kodakaraensis KOD1 and comparison with Pyrococcus genomes”, Cold Spring Harbor Laboratory Press, vol. 15, No. 3, Mar. 2005, pp. 352-363. |
| Foophow, Tita, “Crystal Structure of a Subtilisin Homologue, Tk-SP, from Thermococcus kodakaraensis: Requirement of a C-terminal β-Jelly Roll Domain for Hyperstability”, J. Mol. Biol., vol. 400, No. 4, Jul. 2010, pp. 865-877. |
| International Search Report issued Oct. 6, 2009 in International (PCT) Application No. PCT/JP2009/063547. |
| Y. Kannan et al., “Active Subtilisin-Like Protease from a Hyperthermophilic Archaeon in a Form with a Putative Prosequence”, Applied and Environmental Microbiology, vol. 67, No. 6, pp. 2445-2452, Jun. 2001. |
| M. Pulido et al., “Ca2+-Dependent Maturation of Subtilism from a Hyperthermophilic Archaeon, Thermococcus kodakaraensis: the Propeptide is a Potent Inhibitor of the Mature Domain but is not Required for its Folding”, Applied and Environmental Microbiology, vol. 72, No. 6, pp. 4154-4162, Jun. 2006. |
| M. A. Pulido et al., “Directed Evolution of Tk-Subtilisin from a Hyperthermophilic Archaeon: Identification of a Single Amino Acid Substitution Responsible for Low-Temperature Adaption”, Protein Engineering, Design & Selection, vol. 20, No. 3, pp. 143-153, 2007. |
| S. Tanaka et al., “Crystal Structure of Unautoprocessed Precursor of Subtilisin from a Hyperthermophilic Archaeon”, The Journal of Biological Chemistry, vol. 282, No. 11, pp. 8246-8255, Mar. 16, 2007. |
| S. Tanaka et al., “Four New Crystal Structures of Tk-Subtilisin in Unautoprocessed, Autoprocessed and Mature Forms: Insight into Structural Changes during Maturation”, J. Mol. Biol., vol. 372, pp. 1055-1069, 2007. |
| M. A. Pulido et al., “Requirement of Left-Handed Glycine Residue for High Stability of the Tk-Subtilisin Propeptide as Revealed by Mutational and Crystallographic Analysis”, J. Mol. Biol., vol. 374, pp. 1359-1373, 2007. |
| T. Fukui et al., Definition: Subtilisin-like serine protease, Database DDBJ/EMBL/GenBank [online], Oct. 31, 2006, Accession No. Q5J1Z5, http://www.ncbi.nlm.nih.gov/protein/74506265. |
| Number | Date | Country | |
|---|---|---|---|
| 20110143421 A1 | Jun 2011 | US |
